Spots Global Cancer Trial Database for MRI Iron Oxide Imaging for Lymph Node Staging in Esophageal Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: MRI Iron Oxide Imaging for Lymph Node Staging in Esophageal Cancer

Official Title: MRI Iron Oxide Imaging for Lymph Node Staging in Esophageal Cancer

Study ID: NCT02689401

Conditions

Esophageal Cancer

Interventions

Ferumoxytol

MRI 3T scanner

Study Description

Brief Summary: This research study is evaluating a new imaging method using MRI (magnetic resonance imaging) to evaluate lymph nodes for evidence of tumor spread from esophageal cancer. This MRI study involves an intravenous contrast called Ferumoxytol (FerahemeTM).

Detailed Description: This research study is a Pilot clinical trial, which is the first time investigators are examining this study intervention. This study tests the safety of the investigational intervention (MRI imaging with Ferumoxytol) and assesses the feasibility of identifying malignant lymph nodes (lymph nodes that have tumor in them) by comparing the experimental MRI findings with the final pathology report from surgery. This iron-based agent currently has approval from the U.S. Food and Drug Administration (FDA) for use in iron replacement therapy, however, its use in MRI imaging is not FDA-approved and is thus experimental in this trial.